The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma

Jeffrey D. Altenburg, Sherif Farag

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Multiple myeloma (MM) remains an incurable malignancy indicating a need for continued investigation of novel therapies. Recent studies have highlighted the role of cyclin-dependent kinases (CDK) in the pathogenesis of MM. PD0332991 (Palbociclib) is an orally bioavailable, highly selective inhibitor of the CDK4/6-cyclin complex and downstream retinoblastoma protein (Rb) activation pathway that induces cell cycle arrest in the G1 phase. Areas covered: In this review, the authors summarize the role of the CDK4/ 6 signaling pathway in MM. They also summarize the development of PD0332991 as a specific inhibitor of CDK4/6, and the reported preclinical and clinical data supporting the potential role of PD0332991 in MM. Expert opinion: While PD0332991 is essentially cytostatic, inducing prolonged G1 arrest, it enhances the cytotoxic effect of other agents effective in MM, including bortezomib and lenalidomide, as confirmed in early phase clinical trials. However, with a plethora of other drugs of different classes being tested in MM, further development of PD0332991 will depend on defining the most efficacious combination with least toxicity. An unexplored opportunity remains the potential protective effect of PD0332991 against lytic bone lesions of MM. The next few years are likely to better define the place of PD0332991 in the treatment of MM.

Original languageEnglish
Pages (from-to)261-271
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Multiple Myeloma
Retinoblastoma Protein
Cyclins
Cyclin-Dependent Kinases
palbociclib
Expert Testimony
G1 Phase
Cytostatic Agents
Cell Cycle Checkpoints
Clinical Trials
Bone and Bones
Pharmaceutical Preparations
Neoplasms

Keywords

  • CDK4/6
  • Cell cycle
  • Multiple myeloma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma. / Altenburg, Jeffrey D.; Farag, Sherif.

In: Expert Opinion on Investigational Drugs, Vol. 24, No. 2, 01.02.2015, p. 261-271.

Research output: Contribution to journalArticle

@article{2706abb785e748f6b796af96d5041d0b,
title = "The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma",
abstract = "Introduction: Multiple myeloma (MM) remains an incurable malignancy indicating a need for continued investigation of novel therapies. Recent studies have highlighted the role of cyclin-dependent kinases (CDK) in the pathogenesis of MM. PD0332991 (Palbociclib) is an orally bioavailable, highly selective inhibitor of the CDK4/6-cyclin complex and downstream retinoblastoma protein (Rb) activation pathway that induces cell cycle arrest in the G1 phase. Areas covered: In this review, the authors summarize the role of the CDK4/ 6 signaling pathway in MM. They also summarize the development of PD0332991 as a specific inhibitor of CDK4/6, and the reported preclinical and clinical data supporting the potential role of PD0332991 in MM. Expert opinion: While PD0332991 is essentially cytostatic, inducing prolonged G1 arrest, it enhances the cytotoxic effect of other agents effective in MM, including bortezomib and lenalidomide, as confirmed in early phase clinical trials. However, with a plethora of other drugs of different classes being tested in MM, further development of PD0332991 will depend on defining the most efficacious combination with least toxicity. An unexplored opportunity remains the potential protective effect of PD0332991 against lytic bone lesions of MM. The next few years are likely to better define the place of PD0332991 in the treatment of MM.",
keywords = "CDK4/6, Cell cycle, Multiple myeloma",
author = "Altenburg, {Jeffrey D.} and Sherif Farag",
year = "2015",
month = "2",
day = "1",
doi = "10.1517/13543784.2015.993753",
language = "English",
volume = "24",
pages = "261--271",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma

AU - Altenburg, Jeffrey D.

AU - Farag, Sherif

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Introduction: Multiple myeloma (MM) remains an incurable malignancy indicating a need for continued investigation of novel therapies. Recent studies have highlighted the role of cyclin-dependent kinases (CDK) in the pathogenesis of MM. PD0332991 (Palbociclib) is an orally bioavailable, highly selective inhibitor of the CDK4/6-cyclin complex and downstream retinoblastoma protein (Rb) activation pathway that induces cell cycle arrest in the G1 phase. Areas covered: In this review, the authors summarize the role of the CDK4/ 6 signaling pathway in MM. They also summarize the development of PD0332991 as a specific inhibitor of CDK4/6, and the reported preclinical and clinical data supporting the potential role of PD0332991 in MM. Expert opinion: While PD0332991 is essentially cytostatic, inducing prolonged G1 arrest, it enhances the cytotoxic effect of other agents effective in MM, including bortezomib and lenalidomide, as confirmed in early phase clinical trials. However, with a plethora of other drugs of different classes being tested in MM, further development of PD0332991 will depend on defining the most efficacious combination with least toxicity. An unexplored opportunity remains the potential protective effect of PD0332991 against lytic bone lesions of MM. The next few years are likely to better define the place of PD0332991 in the treatment of MM.

AB - Introduction: Multiple myeloma (MM) remains an incurable malignancy indicating a need for continued investigation of novel therapies. Recent studies have highlighted the role of cyclin-dependent kinases (CDK) in the pathogenesis of MM. PD0332991 (Palbociclib) is an orally bioavailable, highly selective inhibitor of the CDK4/6-cyclin complex and downstream retinoblastoma protein (Rb) activation pathway that induces cell cycle arrest in the G1 phase. Areas covered: In this review, the authors summarize the role of the CDK4/ 6 signaling pathway in MM. They also summarize the development of PD0332991 as a specific inhibitor of CDK4/6, and the reported preclinical and clinical data supporting the potential role of PD0332991 in MM. Expert opinion: While PD0332991 is essentially cytostatic, inducing prolonged G1 arrest, it enhances the cytotoxic effect of other agents effective in MM, including bortezomib and lenalidomide, as confirmed in early phase clinical trials. However, with a plethora of other drugs of different classes being tested in MM, further development of PD0332991 will depend on defining the most efficacious combination with least toxicity. An unexplored opportunity remains the potential protective effect of PD0332991 against lytic bone lesions of MM. The next few years are likely to better define the place of PD0332991 in the treatment of MM.

KW - CDK4/6

KW - Cell cycle

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84921264977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921264977&partnerID=8YFLogxK

U2 - 10.1517/13543784.2015.993753

DO - 10.1517/13543784.2015.993753

M3 - Article

VL - 24

SP - 261

EP - 271

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 2

ER -